Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)
CAPS Rating:
A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.
RSS Headlines
Fool UK
Recs
Promising Lilly partnership, cash flows trending positive, and products in development that will be game-changing for the treatment of diabetes.